StockNews.AI

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc. - GALT

StockNews.AI • 4 hours

GALTVRTXABBV
High Materiality9/10

Information

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves...

Original source

AI Summary

Pomerantz LLP investigates potential securities fraud claims against GALT. Galectin's stock plummeted 28.9% following unresolved FDA trial design discussions. Key aspects of the upcoming clinical trial for belapectin remain unresolved.

Sentiment Rationale

GALT's significant stock drop indicates strong investor concerns and potential fraud implications.

Trading Thesis

Immediate investor sentiment may worsen due to ongoing investigations and uncertainty.

Market-Moving

  • Pomerantz LLP investigates potential securities fraud claims against GALT.
  • Galectin's stock plummeted 28.9% following unresolved FDA trial design discussions.
  • Key aspects of the upcoming clinical trial for belapectin remain unresolved.

Key Facts

  • Pomerantz LLP investigates potential securities fraud claims against GALT.
  • Galectin's stock plummeted 28.9% following unresolved FDA trial design discussions.
  • Key aspects of the upcoming clinical trial for belapectin remain unresolved.

Companies Mentioned

  • GALT (GALT)
  • VRTX (VRTX)
  • ABBV (ABBV)

Corporate Developments

Ongoing investigations and trial uncertainties directly affect investor confidence in GALT.

Investor Alert: Pomerantz Law Firm Investigates Claims Against Galectin Therapeutics Inc. (GALT)

On January 13, 2026, Pomerantz LLP announced an investigation into potential claims on behalf of investors of Galectin Therapeutics Inc. (NASDAQ: GALT). This inquiry is focused on allegations that Galectin and specific officers or directors may have engaged in securities fraud or other unlawful business practices.

Details of the Investigation

Investors with information about this matter are encouraged to reach out to Danielle Peyton at newaction@pomlaw.com or by calling 646-581-9980, extension 7980. The legal team at Pomerantz LLP specializes in class actions related to corporate misconduct and securities fraud, making their investigation significant for affected GALT shareholders.

Recent Developments at Galectin

On December 19, 2025, Galectin Therapeutics released a press statement revealing that the U.S. Food and Drug Administration (FDA) responded in writing to the Company's Type C meeting request regarding its development program for belapectin, an investigational galectin-3 inhibitor. The announcement indicated a shift from an anticipated in-person meeting to a written response, which has raised questions among investors.

Galectin stated that it intends to pursue a follow-up Type C meeting with the FDA to nail down the components of its next clinical trial design. While there appears to be alignment with the FDA regarding the proposed patient population for the registration trial, several crucial aspects of the trial design are still unresolved.

This news had a substantial impact on Galectin’s stock performance, with shares dropping by $1.78, or 28.9%, to close at $4.38 per share on December 19, 2025.

About Pomerantz LLP

Pomerantz LLP is recognized as one of the leading firms in corporate, securities, and antitrust class litigation. Founded by Abraham L. Pomerantz, a pioneer in the class action field, the firm has expanded over the last 85 years and continues to advocate for victims of securities fraud and breaches of fiduciary duty. With offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz has a strong track record of securing multimillion-dollar judgments on behalf of class members.

For further information, please visit www.pomlaw.com.

Contact Information

For inquiries relative to the investigation, please contact:

Related News